The current stock price of ATAI is 4.485 USD. In the past month the price increased by 2.08%. In the past year, price increased by 225%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.18 | 960.08B | ||
| JNJ | JOHNSON & JOHNSON | 20.26 | 506.66B | ||
| MRK | MERCK & CO. INC. | 11.34 | 248.07B | ||
| PFE | PFIZER INC | 8.09 | 147.12B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8 | 106.84B | ||
| ZTS | ZOETIS INC | 18.89 | 52.77B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.35 | 22.17B | ||
| VTRS | VIATRIS INC | 4.94 | 13.26B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.02 | 10.50B | ||
| CORT | CORCEPT THERAPEUTICS INC | 98.89 | 9.15B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.40B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.11B |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI BECKLEY NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND 100022 NL
CEO: Florian Brand
Employees: 54
Phone: 31207932536
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
The current stock price of ATAI is 4.485 USD. The price increased by 1.47% in the last trading session.
ATAI does not pay a dividend.
ATAI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
17 analysts have analysed ATAI and the average price target is 12.24 USD. This implies a price increase of 172.91% is expected in the next year compared to the current price of 4.485.
ATAI BECKLEY NV (ATAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
The Revenue of ATAI BECKLEY NV (ATAI) is expected to grow by 468.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 5 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 97.32% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ATAI. ATAI has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.24% | ||
| ROE | -93.44% | ||
| Debt/Equity | 0 |
17 analysts have analysed ATAI and the average price target is 12.24 USD. This implies a price increase of 172.91% is expected in the next year compared to the current price of 4.485.
For the next year, analysts expect an EPS growth of 30.67% and a revenue growth 468.61% for ATAI